pharmaphorum

JULY 2, 2025

The ability to streamline clinical trials, personalise treatments, and accelerate drug development is groundbreaking. A recent report found that 64% of pharmaceutical executives are hesitant to integrate AI into drug development due to concerns over security. The opportunity ahead is enormous.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Development 52

pharmaphorum

OCTOBER 11, 2022

Asked how he made the shift from working out the structure of proteins and how molecules bind to those proteins, to the founding of pharmaphorum and focusing on the digital space, his answer was clear: communication. Tunnah realised, in fact, that that communicative passion lay within himself and wasn’t satisfied by academic work.

Communication 98

Communication Diabetes Drug Development 98

Pharmaceutical Technology

APRIL 6, 2023

The US Food and Drug Administration (FDA) has released the fourth and final chapter in a series of guidance documents designed to support patient-focused drug development. The draft guidance, released on March 5, is open for comments until May 7, after which it will replace an earlier 2009 guidance for the industry.

Drug Development 52

Drug Development Documentation Communication 52

European Pharmaceutical Review

SEPTEMBER 14, 2023

In 2001 and 2007, through 2009, the economy was hit hard. There was a significant slowdown in drug development, clinical trials, and new drugs coming to market. EMA prepares for winter antibiotic shortages That slowdown resulted in 211 drug shortages in 2010—the highest number recorded in a single year at the time.

Drug Development 98

Drug Development Drug Pricing Communication 98

Putting Patients First Blog

JULY 10, 2023

MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. MACC Commissioner United States Food and Drug Administration 5 630 Fishers Lane, Rm. The NHC was a strong supporter of the inclusion of these guidances in the Prescription Drug User Fee Act (PDUFA) VI agreement. Califf M.D., Califf M.D.,

Communication 40

Communication Drug Development Packaging Labelling 40

pharmaphorum

MARCH 30, 2021

“There’s a lot that drug development for more common diseases could learn from rare disease R&D”. I think there’s a lot that drug development for more common diseases could learn from rare disease R&D.”. We have to be innovative to get around those challenges. Rare diseases during COVID.

Hospitals 111

Hospitals Communication Drug Development Pharmaceutical Companies 111

Pharmaceutical Technology

FEBRUARY 1, 2023

During the 2009–19 period, children in the US ages five years and younger accounted for 58, 000 annual RSV-related hospitalisations and 100–500 annual deaths. Pharmaceutical companies are pushing to develop drugs and vaccines for RSV with these populations in mind. GlobalData is the parent company of Pharmaceutical Technology.

Vaccines 64

Vaccines Drug Development Pharmaceutical Companies Pharmaceutical Companies 64